drugset
drugset / Trial / NCT03142724

Assessment of the Biodistribution and Safety of [18F]MNI-968 in Healthy Subjects

NCT03142724 ↗

Phase 1 Completed 6 enrolled Molecular NeuroImaging
NaSingle-groupOpen-labelOther

Summary

The overall goal of this protocol is to evaluate the biodistribution of \[18F\]MNI-968 as a D1 receptor targeted radiopharmaceutical.

Timeline

Start
2017-05-01
Primary completion
2018-03-01
Completion
2018-03-01

Drugs

EvaluationDrugModalityDoseRoute
Subject [18F]MNI-968 Unknown — —

Indications

No indication recorded.